Topical Antiperspirant for Hand-Foot Syndrome

Completed · Phase 2

Conditions studied: Palmar-plantar Erythrodysesthesia

In brief

The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.

Key facts

Study ID

NCT00213993

Run by

University of Wisconsin, Madison

People needed

14

Starts

2005-05-01

Expected to finish

2007-01-01

Last updated by the study team

2015-10-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has not previously received a regimen that includes 5-fluorouracil
• > 18 years old
• No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant

You may not qualify if…

• < 18 years of age

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.